BIOGEN INC. is 17.8x more valuable than RECURSION PHARMACEUTICALS, INC. by market capitalization ($28.68 B vs $1.61 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | RXRX | BIIB |
|---|---|---|
| Market cap | $1.61 B | $28.68 B |
| US-listed rank | #2258 | #476 |
| Revenue (latest FY) | $74.68M | $9.89B |
| Net income (latest FY) | -$644.76M | $1.29B |
| Net margin | -863.4% | 13.1% |
| P/E (trailing FY) | - | 22.2 |
| SEC filings | 908 | 2,690 |
BIOGEN INC. is 17.8x more valuable than RECURSION PHARMACEUTICALS, INC. by market capitalization ($28.68 B vs $1.61 B).
In their latest fiscal years, RECURSION PHARMACEUTICALS, INC. reported $74.68M in revenue while BIOGEN INC. reported $9.89B.
Full pages: RECURSION PHARMACEUTICALS, INC. and BIOGEN INC., or browse the full rankings.